Search

Author/Creator Patekar, Manmath

1. Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients. Issue 2 (7th January 2020)

Authors:
Bruin, Gerard; Hockey, Hans‐Ulrich P.; La Stella, Phillip; Sigurgeirsson, Bárdur; Fu, Rong; Patekar, Manmath; Charef, Pascal; Woessner, Ralph; Boutouyrie‐Dumont, Bruno
Journal:
British journal of clinical pharmacology
Issue:
Volume 86:Issue 2(2020)
Page Start:
338
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study. (3rd April 2022)

Authors:
Sigurgeirsson, Bardur; Schäkel, Knut; Hong, Chih-Ho; Effendy, Isaak; Placek, Waldemar; Rich, Phoebe; Keefe, Deborah; Bruin, Gerard; Charef, Pascal; Fu, Rong; Hampele, Isabelle; Patekar, Manmath
Journal:
Journal of dermatological treatment
Issue:
Volume 33:Number 3(2022)
Page Start:
1718
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52‐week results from MATURE, a randomized, placebo‐controlled trial. Issue 3 (8th January 2022)

Authors:
Sigurgeirsson, Bardur; Browning, John; Tyring, Stephen; Szepietowski, Jacek C.; Rivera‐Díaz, Raquel; Effendy, Isaak; Keefe, Deborah; Bruin, Gerard; Paguet, Bertrand; Fu, Rong; Hampele, Isabelle; Reinhardt, Maximilian; Patekar, Manmath
Journal:
Dermatologic therapy
Issue:
Volume 35:Issue 3(2022)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. (1st June 2022)

Authors:
Augustin, Matthias; Reich, Kristian; Yamauchi, Paul; Pinter, Andreas; Bagel, Jerry; Dahale, Swapnil; You, Ruquan; Bruin, Gerard; Djimopoulos, Jimena; Paguet, Bertrand; Charef, Pascal; Patekar, Manmath; Keefe, Deborah
Journal:
British journal of dermatology
Issue:
Volume 186:Number 6(2022)
Page Start:
942
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. (8th April 2022)

Authors:
Augustin, Matthias; Reich, Kristian; Yamauchi, Paul; Pinter, Andreas; Bagel, Jerry; Dahale, Swapnil; You, Ruquan; Bruin, Gerard; Djimopoulos, Jimena; Paguet, Bertrand; Charef, Pascal; Patekar, Manmath; Keefe, Deborah
Journal:
British journal of dermatology
Issue:
Volume 186:Number 6(2022)
Page Start:
942
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 9999 (19th September 2015)

Authors:
McInnes, Iain B; Mease, Philip J; Kirkham, Bruce; Kavanaugh, Arthur; Ritchlin, Christopher T; Rahman, Proton; van der Heijde, Désirée; Landewé, Robert; Conaghan, Philip G; Gottlieb, Alice B; Richards, Hanno; Pricop, Luminita; Ligozio, Gregory; Patekar, Manmath; Mpofu, Shephard
Journal:
Lancet
Issue:
Volume 386:Issue 9999(2015)
Page Start:
1137
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗